关于鱼油对精神病患者临床症状和心理社会功能影响的研究一直不一致。我们进行了这项系统评价和荟萃分析,以总结有关口服鱼油对精神病患者心理功能影响的现有数据。三个在线数据库,包括PubMed,Scopus,和WebofScience进行了搜索,以确定2021年4月发表的相关研究。接触是口服鱼油补充剂。阳性和阴性综合征量表(PANSS)简明精神病学评定量表(BPRS),全球功能评估(GAF)是我们的结果衡量标准。纳入了17项随机临床试验,涉及1390名患者。口服鱼油摄入后没有观察到PANSS的变化[加权平均差(WMD):-0.87;95%CI:-16.99,15.26;P=0.92]。在非线性剂量响应分析中,在<10wk的鱼油补充剂和PANSS之间观察到显著的负相关(WMD:-10;P非线性=0.02).尽管对4项研究的分析表明,摄入鱼油后BPRS无显著降低(WMD:-2.990;95%CI:-6.42,0.44;P=0.08),非线性剂量-反应分析显示,剂量(>2200mg/d)和鱼油补充剂持续时间(<15wk)与BPRS评分(WMD:-8;P-非线性=0.04)之间呈显著负相关.来自6项随机临床试验的联合效应大小显示口服鱼油后GAF显著增加(WMD:6.66;95%CI:3.39,9.93;P<0.001)。总之,我们没有发现补充鱼油后PANSS和BPRS评分有任何显著变化.然而,口服鱼油摄入显著有助于GAF评分的改善。这是第一个荟萃分析,以检查鱼油对PANSS的心理功能得分的影响,BPRS,同时GAF。
Research on the effects of fish oil on clinical symptoms and psychosocial functioning in people with psychosis has been inconsistent. We conducted this systematic
review and meta-analysis to summarize the available data on the effects of oral intake of fish oil on psychological functioning in patients with psychosis. Three online databases including PubMed, Scopus, and Web of Science were searched to identify relevant studies published by April 2021. The exposure was oral fish-oil supplementation. The Positive and Negative Syndrome Scale (PANSS), the Brief Psychiatric Rating Scale (BPRS), and the Global Assessment of Functioning (
GAF) were our outcome measures. Seventeen randomized clinical trials involving 1390 patients were included. No change in PANSS was observed following oral fish-oil intake [weighted mean difference (WMD): -0.87; 95% CI: -16.99, 15.26; P = 0.92]. In a nonlinear dose-response analysis, a significant inverse association was observed between <10 wk of fish-oil supplementation and PANSS (WMD: -10; P-nonlinearity = 0.02). Although analysis of 4 studies showed a nonsignificant reduction in BPRS after fish-oil intake (WMD: -2.990; 95% CI: -6.42, 0.44; P = 0.08), a nonlinear dose-response analysis revealed significant inverse associations between dose (>2200 mg/d) and duration of fish-oil supplementation (<15 wk) with BPRS score (WMD: -8; P-nonlinearity = 0.04). Combined effect sizes from 6 randomized clinical trials showed significant increases in
GAF after oral administration of fish oil (WMD: 6.66; 95% CI: 3.39, 9.93; P < 0.001). In conclusion, we did not find any significant changes in PANSS and BPRS scores following fish-oil supplementation. Nevertheless, oral fish-oil intake significantly contributed to improvement in
GAF scores. This is the first meta-analysis to examine the effects of fish oil on the psychological functioning scores of PANSS, BPRS, and
GAF simultaneously.